Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 2 completed trials

    Completion Rate
    100%(2/2)
    Active Trials
    1(25%)
    Results Posted
    50%(1 trials)

    Phase Distribution

    Phase 1
    3
    75%
    Phase 2
    1
    25%

    Phase Distribution

    3

    Early Stage

    1

    Mid Stage

    0

    Late Stage

    Phase Distribution4 total trials
    Phase 1Safety & dosage
    3(75.0%)
    Phase 2Efficacy & side effects
    1(25.0%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    66.7%

    2 of 3 finished

    Non-Completion Rate

    33.3%

    1 ended early

    Currently Active

    1

    trials recruiting

    Total Trials

    4

    all time

    Status Distribution
    Active(1)
    Completed(2)
    Terminated(1)

    Detailed Status

    Completed2
    Active, not recruiting1
    Withdrawn1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    4
    Active
    1
    Success Rate
    100.0%
    Most Advanced
    Phase 2

    Trials by Phase

    Phase 13 (75.0%)
    Phase 21 (25.0%)

    Trials by Status

    completed250%
    active_not_recruiting125%
    withdrawn125%

    Recent Activity

    1 active trials
    Showing 4 of 4
    active_not_recruitingphase_1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

    NCT02291848
    completedphase_2

    TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer

    NCT03093350
    withdrawnphase_1

    (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).

    NCT05134740
    completedphase_1

    TAA-Specific CTLS for Solid Tumors (TACTASOM)

    NCT02239861

    Clinical Trials (4)

    Showing 4 of 4 trials
    NCT02291848Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

    Active Not Recruiting
    NCT03093350Phase 2

    TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer

    Completed
    NCT05134740Phase 1

    (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).

    Withdrawn
    NCT02239861Phase 1

    TAA-Specific CTLS for Solid Tumors (TACTASOM)

    Completed

    All 4 trials loaded

    Drug Details

    Intervention Type
    Biological
    Total Trials
    4